The dysregulation of PHB2 in cardiomyopathies has underscored its promise as a therapeutic target for ameliorating mitochondrial dysfunction and enhancing cardiac outcomes in septic and inflammatory scenarios. The gene discussed is PHB2; the disease is cardiomyopathy.